A Phase 2 interventional study of Neutral Fluid Balance Strategy in Traumatic Brain Injury, Severe Traumatic Brain Injury and Acute Brain Injury, sponsored by Erasme University Hospital. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Erasme University Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Brain Injuries, Traumatic with a site in Italy — 11 open to participants now, 17 under way, 1 of them phase 3. Brain Injuries, Traumatic · Italy.
Among the 45 studies in Brain Injuries, Traumatic with a site in Italy, this one is the 8th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 in phase 2, reaches primary completion later than 13 of the 16 other live ones, and was the 41st registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →11 of the 45 studies in Brain Injuries, Traumatic with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Don Carlo Gnocchi ETS · Sites in Italy
Ages 18–75 · Healthy volunteers
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18+
Mario Negri Institute for Pharmacological Research · Sites in Italy
Ages 18+
University of Milano Bicocca · Sites in Italy
Ages 18–80
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3 · Phase 4 3
First in 2002; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 88 is above the median of 52 across 1,091 interventional studies indexed under Brain Injuries, Traumatic.
Median enrollment 30 across the 24 interventional studies, 238 across the 20 observational. Of the 20 that completed or were terminated, 5 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 45 have an industry lead sponsor. The 10 most frequent:
Erasme University Hospital is the lead sponsor of 182 studies on the registry; 35 are open to participants now.
Erasme University Hospital has 1 study filed under Brain Injuries, Traumatic — fewer than ten, so there is no comparison to draw.
6 of the studies in Brain Injuries, Traumatic with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04459806University of Milano BicoccaIntracranial PrEssure Time dOse (ImPETO) | 2026-11-30 |
| NCT04559724IRCCS San Raffaele RomaGait Training Through a Novel Over-ground Wearable Robotic System in People With Pyramidal Hemisyndromes | 2026-12 |
| NCT06920784Istituti Clinici Scientifici Maugeri SpAPrismatic Adaptation in Cognitive Rehabilitation | 2026-12-31 |
| NCT07456475Istituto per la Ricerca e l'Innovazione BiomedicaMetaverse Applications in Clinical Neurorehabiliation: Device Feasibility | 2027-04-01 |
| NCT06834659Università Vita-Salute San RaffaeleCorrelation and Rapid Analysis of Neurological Injury Using Markers | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 45 studies in Brain Injuries, Traumatic with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The LIMIT-TBI trial is a multicenter, international, randomized, phase II clinical trial designed to evaluate the feasibility and safety of targeting a neutral fluid balance compared to standard care in critically ill adult patients with traumatic brain injury (TBI).
Fluid therapy is a cornerstone of TBI management, but optimal fluid balance remains uncertain, with both fluid overload and restriction potentially leading to adverse outcomes. This study aims to determine whether maintaining a daily fluid balance close to zero (±500 mL) during the first 5 days of ICU admission is achievable and safe.
Participants will be randomized within 48 hours of ICU admission to either a protocolized neutral fluid balance strategy or standard care. Outcomes include feasibility of achieving the target balance, organ complications, hemodynamic parameters, ICU resource utilization, and mortality and neurological outcomes up to 6 months.
Severe traumatic brain injury (TBI) is a major cause of mortality and long-term disability worldwide and frequently requires intensive care management. In these patients, preventing secondary brain injury is essential and involves optimizing cerebral perfusion pressure (CPP), systemic hemodynamics, and organ function. Fluid therapy plays a central role in achieving these goals.
However, the optimal fluid management strategy in TBI remains unclear. Excessive fluid administration may lead to complications such as pulmonary edema and worsening cerebral edema, while restrictive strategies may increase the risk of hypovolemia and impaired cerebral perfusion. Current guidelines provide limited or no specific recommendations due to the lack of high-quality randomized evidence. Observational data suggest that a more positive fluid balance is associated with worse outcomes, but causality has not been established.
The LIMIT-TBI trial is a pragmatic, international, multicenter, randomized, unblinded, parallel-group phase II study designed to address this evidence gap. Adult patients with TBI admitted to the ICU will be randomized within 48 hours in a 1:1 ratio to either:
A neutral fluid balance strategy, targeting a daily balance of 0 mL (±500 mL) and cumulative neutrality over the first 5 days, using a protocolized approach combining fluid restriction, vasopressors, and diuretics when needed; A standard of care strategy, in which fluid administration is guided by local practice and clinician judgment.
In the intervention group, all fluid inputs (intravenous fluids, medications, and enteral nutrition) and outputs are strictly monitored. Maintenance fluids are minimized, and adjustments are made daily to achieve neutrality while maintaining adequate mean arterial pressure and cerebral perfusion pressure targets.
The primary objective is to assess the feasibility and safety of achieving a neutral fluid balance, defined as maintaining a daily balance within ±500 mL. Secondary outcomes include systemic complications, hemodynamic parameters (including CPP), fluid administration metrics, vasopressor and diuretic use, organ support-free days, and ICU/hospital mortality. Long-term outcomes include 6-month mortality and neurological status assessed using the Glasgow Outcome Scale Extended (GOSE).
A total of 88 patients will be enrolled to provide adequate power to detect differences in fluid balance between groups. Statistical analyses will include linear mixed models for repeated measures and appropriate comparative tests for secondary outcomes, with multiple imputation for missing primary endpoint data.
This trial will provide important preliminary randomized evidence on fluid management in TBI and inform the design of future large-scale trials aimed at improving outcomes in this high-risk population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants randomized to the experimental arm will receive a protocolized fluid management strategy targeting a neutral fluid balance (0 ± 500 mL per day) during the first 5 days following ICU admission. All fluid inputs (intravenous fluids, medications, enteral nutrition) and outputs (urine, drains, gastrointestinal losses, etc.) will be strictly monitored and included in the daily balance calculation. Fluid administration will be minimized, and no routine maintenance fluids will be administered unless required to ensure a minimum daily intake of approximately 1 L (including medications and nutrition). If the daily fluid balance exceeds ±500 mL, adjustments will be made in subsequent days by reducing fluid administration and/or introducing diuretics to achieve cumulative neutrality. Hemodynamic targets (mean arterial pressure ≥70 mmHg, systolic arterial pressure ≥100 mmHg, and/or cerebral perfusion pressure ≥60 mmHg) will be maintained using vasopressors (e.g., norepinephrine)
Other: Neutral Fluid Balance Strategy
Participants randomized to the control arm will receive standard fluid management according to local ICU practice and clinician judgment. Intravenous fluids may be administered as maintenance therapy if part of local protocols, and to correct hypovolemia, dehydration, electrolyte imbalances, or ongoing losses. Hemodynamic targets, including cerebral perfusion pressure, will be achieved using fluids and/or vasopressors at the discretion of the treating clinician, without a predefined protocol for fluid balance. Fluid balance will be monitored but no specific target for neutrality will be enforced.
Protocolized strategy targeting a daily fluid balance of 0 ± 500 mL for 5 days using restricted fluids, diuretics, and vasopressors to maintain hemodynamic and cerebral perfusion targets.
Feasibility of achieving a neutral daily fluid balance
Proportion of patients achieving a mean daily fluid balance within 0 ± 500 mL during the 5 days after ICU admission - mean daily fluid balance will be measured at day 5 as the mean of the fluid balances of the 5 previous days
Time frame: At 5 days after randomisation
Incidence of systemic organ complications
Incidence of new organ dysfunction or complications during ICU stay.
Time frame: ICU discharge
Cerebral perfusion pressure (CPP)
Mean and daily cerebral perfusion pressure during ICU stay.
Time frame: From randomisation to day 5 after randomisation
Daily fluid balance and fluid input
Mean daily fluid balance and total fluid input during the first 5 days
Time frame: From randomisation to day 5 after randomisation
Vasopressor and diuretic use
Total and daily dose of vasopressors and diuretics during ICU stay.
Time frame: ICU discharge
Vasopressor-free days
Number of days alive and free from vasopressor support.
Time frame: From randomisation to day 28 after randomisation
Ventilator-free days
Number of days alive and free from invasive mechanical ventilation.
Time frame: From randomisation to day 28 after randomisation
Therapy intensity level (TIL)
Maximum therapy intensity level during the intervention period.
Time frame: At day 5 after randomisation
ICU and hospital mortality
All-cause mortality during ICU and hospital stay.
Time frame: Hospital discharge
Neurological outcome (GOSE)
Functional neurological outcome assessed by Glasgow Outcome Scale Extended.
Time frame: Hospital discharge
Long-term mortality
All-cause mortality at follow-up.
Time frame: 180 days after randomization
Long-term neurological outcome (GOSE)
Functional neurological outcome assessed by Glasgow Outcome Scale Extended. Scale 1 to 8, 1= dead; 8=good recovery no social and mental deficits
Time frame: 180 days after randomization
Plan to share: Undecided
Started Jul 2025 (actual). Primary completion is estimated for Dec 2028, 41 months after the start.
Of 47 phase 2 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 30. This study's planned 41 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.